Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted ConferenceBusiness Wire • 12/20/23
FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect AdultsBusiness Wire • 12/19/23
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract CancerBusiness Wire • 12/18/23
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial CancerBusiness Wire • 12/15/23
FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKIBusiness Wire • 12/15/23
Merck (MRK) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 12/14/23
Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock JumpsInvestopedia • 12/14/23
Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's KeytrudaMarket Watch • 12/14/23
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?Investors Business Daily • 12/14/23
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following CompAccesswire • 12/14/23
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung CancerBusiness Wire • 12/11/23